Apparently the ceiling is in sight...At $84,000 Gilead Hepatitis C Drug Sets Off Payer Revolt There is a practical limit on what the market can pay for new therapies. http://www.bloomberg.com/news/2014-01-27/at-84-000-gilead-hepatitis-c-drug-sets-off-payer-revolt.html